Abstract Number: 0758 • ACR Convergence 2024
Difficult to Treat Takayasu Arteritis: Comparative Efficacy of Colchicine and Tofacitinib
Background/Purpose: Biologic DMARDs (bDMARDs) are mainstay in management of patients with difficult to treat Takayasu Arteritis (D2TTAK). The cost of long-term biologics is prohibitory in…Abstract Number: 0765 • ACR Convergence 2024
Tocilizumab in Extracranial Large-Vessel Giant Cell Arteritis and Takayasu Arteritis: A Multicentric Observational Comparative Study
Background/Purpose: Tocilizumab (TCZ) seems to be effective in large vessel (LV) vasculitis including giant cell arteritis (GCA) and Takayasu arteritis (TAK). LV-GCA phenotype shares some…Abstract Number: 1561 • ACR Convergence 2024
Association of Large Vessel Vasculitis and Development of SSc and SSc-Associated Antibodies: Impact of Pulmonary Arterial Hypertension
Background/Purpose: Large vessel vasculitis (LVV) comprises a spectrum of rare, potentially life-threatening disorders, including giant cell arteritis (GCA) and Takayasu's arteritis (TAK), defined by granulomatous…Abstract Number: 1615 • ACR Convergence 2024
Is Regular Vascular Imaging Scheduled Essential in the Follow-Up of Takayasu Arteritis? A Large-Scale Multicenter Cohort Study
Background/Purpose: The understanding of progression or minimal disease activity in patients with Takayasu arteritis (TA) can be complicated due to the possibility of mild vascular…Abstract Number: 1631 • ACR Convergence 2024
Serum IL-6 Levels Correlate with Inflammatory Activity in Computerized Tomography Angiography Scans in Takayasu Arteritis
Background/Purpose: Assessing disease activity in Takayasu arteritis (TA) is a significant challenge, and there is no consensus on evaluating inflammatory activity (IA). Previous studies have…Abstract Number: 1632 • ACR Convergence 2024
Multi-vessel Intimal Medial Thickness in Takayasu Arteritis: A Potential Marker for Disease Modification?
Background/Purpose: Ultrasonography can measure vascular intimal-medial thickness (IMT) and delineate the degrees of stenosis in Takayasu arteritis (TAK). Further, higher IMT has been reported in…Abstract Number: 1636 • ACR Convergence 2024
Age-associated B Cells Contribute to Inflammation of Takayasu’s Arteritis in an Antibody-secreting Cell Differentiation Independent Manner
Background/Purpose: Although Takayasu’s arteritis (TAK) is not a prototypical autoantibody-mediated autoimmune disease, several lines of evidence suggested the pathogenic potential of B cells. However, limited…Abstract Number: 1696 • ACR Convergence 2024
Comparison of Mycophenolate Mofetil Plus Methotrexate versus Cyclophosphamide with Sequential Azathioprine for Active Takayasu’s Arteritis: An Open-Label, Randomized-Controlled Trial
Background/Purpose: The management of Takayasu’s arteritis (TAK) is challenging for lack of large-scale, high-quality clinical trials. Cyclophosphamide (CYC) is a conventional first-line immunosuppressant but is…Abstract Number: 2180 • ACR Convergence 2024
The Association Between Age at Diagnosis and Patient-Reported Outcomes in Patients with Vasculitis
Background/Purpose: Vasculitis is a chronic autoimmune condition that significantly impacts patients’ quality of life. It is unknown whether the degree of this impact varies based…Abstract Number: 0522 • ACR Convergence 2024
Hematological Impact Assessment of Tofacitinib, Baricitinib, and Upadacitinib in Rheumatoid Arthritis Treatment
Background/Purpose: Janus kinase (JAK) inhibitors' introduction has significantly revolutionized the therapeutic landscape, notably influencing the management strategies for rheumatoid arthritis (RA). To compare the effects…Abstract Number: 2523 • ACR Convergence 2024
Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms
Background/Purpose: There is no data on which patients biologic immunosuppressive (bIS) treatment should be chosen in Takayasu’s arteritis (TAK). In this study we aimed to…Abstract Number: 0698 • ACR Convergence 2024
Association of Systemic Sclerosis with ANCA-Associated Vasculitis and Large Vessel Vasculitis: Impact of Pulmonary Arterial Hypertension
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune disorder with excessive fibrosis and vasculopathy. While typically non-inflammatory, frank vasculitis can complicate SSc. Concomitant SSc with ANCA-associated…Abstract Number: 2628 • ACR Convergence 2024
Clinical Features, Treatments, and Outcomes of a Large International Cohort of Childhood-onset Takayasu Arteritis: A PedVas Study
Background/Purpose: Takayasu arteritis (TAK) is a rare systemic vasculitis. It occurs most commonly in patients aged < 40 years (y), and 32% of patients present…Abstract Number: 0746 • ACR Convergence 2024
Single-cell RNA-Seq Analysis Reveals Distinct Compositional Characterizations and Transcriptomic Profiles of Macrophages in Takayasu’s Arteritis
Background/Purpose: Macrophages play key roles in the pathogenesis of various inflammatory vascular diseases, such as Takayasu’s arteritis (TAK) and atherosclerosis. However, limited data on the…Abstract Number: 0749 • ACR Convergence 2024
Age at Disease Onset Influences the Clinical Phenotype and Outcome of Patients with Takayasu Arteritis: Results from a Monocentric Cohort of 167 Patients
Background/Purpose: Takayasu arteritis (TAK) typically affects people between the ages of 20 and 40. However, disease onset can span across different age periods. Aim of…
- 1
- 2
- 3
- …
- 7
- Next Page »